Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
US10906905B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 13, 2017 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | Oct 13, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-β inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-β, wherein the definition of each substituent in the general formula (I) is the same as defined in the description.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.